Table 3.

Microbleeds and progression of WML volume.

	Difference in annual progression of WML volume
	Model 1	Model 2	Model 3
No pre-existing microbleeds	Reference	Reference	Reference
Pre-existing microbleeds (all)	−0.03 (−0.15; 0.09)	−0.05 (−0.17; 0.08)	−0.01 (−0.14; 0.11)
Pre-existing strictly lobar	−0.04 (−0.18; 0.10)	−0.06 (−0.20; 0.08)	−0.07 (−0.21; 0.08)
Pre-existing deep or infratentorial	0.01 (−0.19; 0.18)	−0.01 (−0.21; 0.18)	0.09 (−0.11; 0.28)
No incident microbleeds	Reference	Reference	Reference
Incident microbleeds (all)	0.23 (0.05; 0.40)	0.19 (0.01; 0.37)	0.22 (0.04; 0.41)
Incident strictly lobar	0.41 (0.21; 0.62)	0.39 (0.18; 0.61)	0.33 (0.10; 0.55)
Incident deep or infratentorial	−0.10 (−0.37; 0.17)	−0.17 (−0.45; 0.11)	0.02 (−0.28; 0.32)

Model 1: adjusted for age, sex, scan interval, and intracranial volume.

Model 2: as model 1, additionally adjusted for blood pressures, total and HDL cholesterol, smoking, diabetes mellitus, lipid lowering medication, antihypertensive medication, and antiplatelet medication.

Model 3: as model 1, additionally adjusted for apolipoprotein E ε4 genotype.

Values represent differences in annual white matter lesion volume progression in participants with pre-existing and incident microbleeds compared to no microbleeds.

Abbreviations: WML= white matter lesion.